Trial to Investigate the Effect of Dapagliflozin on Ischemia Reperfusion Induced Endothelial Dysfunction

Sponsor
Medical University of Vienna
Study ID
NCT05217654
Phase
PHASE1
Status
Unknown

Conditions

  • Reperfusion Injury
  • Vascular Complications

Eligibility Criteria

Sex
MALE
Age
18 Years - 40 Years
Healthy Volunteers
Accepted

Interventions

  • Dapagliflozin 10mg — DRUG
    Daily orally administration of 10mg dapagliflozin
  • Placebo — DRUG
    Daily orally administration of 10mg dapagliflozin-placebo

Study Details

The aim of the study is to investigate the effect of dapagliflozin or placebo on acetylcholine (Ach)- or nitroglycerin (GTN)-induced vasodilation of the forearm resistance vasculature, as determined by FBF measurement before and 10 minutes after 20 minutes of forearm ischemia.

Key Dates

Start date
Feb 18, 2022
Status verified
Feb 2022
Primary completion
Feb 1, 2023
Completion
Aug 1, 2023

Study Design

Enrollment
32 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Active Comparator: Dapagliflozin
    14 day orally treatment with dapagliflozin
  • Placebo Comparator: Dapagliflozin-placebo
    14 day orally treatment with dapagliflozin - placebo

Primary Outcome Measure

Acetylcholine - Area under the curve forearm blood flow measurement [ Time Frame: 14 days ]

Central Contacts

Related Studies